1	Cardiovascular disease and subsequent risk of psychiatric
2	disorders: a nationwide sibling-controlled study
3	Full author list:
4	Qing Shen ^{1,4} ; Huan Song ^{1,2,3,4} ; Thor Aspelund ⁴ ; Jingru Yu ¹ ; Donghao Lu ^{2,5,8} ; Jóhanna
5	Jakobsdóttir ⁴ ; Jacob Bergstedt ⁵ ; Lu Yi ¹ ; Patrick F. Sullivan ^{1,6} ; Arvid Sjölander ¹ ; Weimin Ye
6	¹ ; Katja Fall ^{5,7} ; Fang Fang, ^{5,*} ; Unnur Valdimarsdóttir ^{4,5,8;*}
7	
8	Author affiliations:
9	¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,
10	Sweden
11	² West China Biomedical Big Data Center, West China Hospital, Sichuan University,
12	Chengdu, China
13	³ Medical Big Data Center, Sichuan University, Chengdu, China
14	⁴ Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík,
15	Iceland
16	⁵ Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
17	Stockholm, Sweden
18	⁶ Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, United
19	States
20	⁷ Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University,
21	Örebro, Sweden
22	⁸ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
23	Massachusetts, United States
24	
25	* Equal contribution

-	~
γ	6
7	υ

- 27 Correspondence to:
- 28 Qing Shen (qing.shen@ki.se)
- 29 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobelsväg 12A,
- 30 171 65 Solna, Sweden.
- 31 Unnur Valdimarsdóttir (unnurav@hi.is)
- 32 Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet,
- 33 Stockholm, Sweden
- 34
- 35 Running title: Cardiovascular disease and psychiatric disorders
- 36 Word count: abstract 344; text 2965; reference 45
- 37 Number of tables/figures: 1 table; 4 figures; 7 supplementary tables 7; 4 supplementary
- 38 figures
- 39
- 40

41 Abstract

42 Background

43 The association between cardiovascular disease (CVD) and selected psychiatric disorders has

- 44 frequently been suggested while inadequate control of familial factors and comorbidities has
- 45 halted causal inferences.

46 Methods

We identified 869 056 patients newly diagnosed with CVD from 1987 to 2016 in Sweden while no history of psychiatric disorders, and 910 178 full siblings of these patients and 10 individually age- and sex-matched unrelated population controls (N=8 690 560). Adjusting for multiple comorbid conditions, we used flexible parametric models and Cox regression to estimate the association of CVD with risk of all subsequent psychiatric disorders, comparing rates of first incident psychiatric disorder among CVD patients with rates among unaffected full siblings and population controls.

54 **Results**

55 The median age at diagnosis was 60 years for patients with cardiovascular disease and 59.2% 56 were male. During up to thirty years of follow-up, the crude incidence rates of psychiatric 57 disorder were 7.1, 4.6 and 4.0 per 1000 person-years for patients with cardiovascular disease, 58 their siblings and population controls. In the sibling comparison, we observed an increased 59 risk of psychiatric disorder during the first year after cardiovascular diagnosis (hazard ratio 60 [HR], 2.74; 95% confidence interval [CI], 2.62-2.87) and thereafter (1.45; 95% CI, 1.42-61 1.48). Increased risks were observed for all types of psychiatric disorders and among all 62 diagnoses of cardiovascular disease. We observed similar associations in the population 63 comparison. Cardiovascular patients who developed a comorbid psychiatric disorder during

64	the first year after diagnosis were at increased risk of subsequent cardiovascular death
65	compared to patients without such comorbidity (HR 1.55; 95% CI 1.44-1.67).
66	Conclusions
67	Patients diagnosed with cardiovascular disease are at an elevated risk for subsequent
68	psychiatric disorders independent of familial factors and comorbid conditions. Cardiovascular
69	patients with comorbid psychiatric disorders are at increased risk of cardiovascular mortality
70	suggesting that surveillance and treatment of psychiatric comorbidities should be considered
71	as an integral part of clinical management of newly diagnosed patients with cardiovascular
72	disease.
73	
74	Funding: this work was supported by the EU Horizon 2020 Research and Innovation Action
75	Grant (CoMorMent, Grant nr. 847776 to UV, PFS and FF), Grant of Excellence, Icelandic
76	Research Fund (grant no. 163362-051 to UV), ERC Consolidator Grant (StressGene, grant
77	no: 726413 to UV), Swedish Research Council (Vetenskapsrådet, award D0886501 to PFS)
78	and US NIMH R01 MH123724 (to PFS).
79	
80	
81	
82	Key words: Cardiovascular disease, psychiatric disorder, sibling, family design
83	
84	

85 Introduction

86 Being diagnosed and living with a major life-threatening disease is stressful and associated 87 with multiple biologic processes that combined may contribute to the development of 88 psychiatric disorders. It is for instance firmly demonstrated that a cancer diagnosis is associated with a rapid rise of psychiatric disorders¹ and self-inflicted injury,² which further is 89 associated with a compromised cancer specific survival.³ Psychiatric comorbidities have also 90 been reported among patients with cardiovascular disease (CVD), e.g. after stroke,⁴ heart 91 failure,⁵ and myocardial infarction.^{6,7} with indications of elevated risk of overall mortality.^{8,9} 92 93 Yet, evidence on the association between CVD and subsequent development of psychiatric 94 disorders is still limited as previous research has mainly relied on selected patient populations 95 instead of complete follow-up of general population as well as limited control of reverse causality and important confounding factors, e.g. familial factors and comorbidities.¹⁰⁻¹² 96 97 We thoroughly searched the existing literature of investigating the association between CVD 98 and clinically confirmed psychiatric disorders or psychiatric symptoms. After excluding most 99 studies with either cross-sectional or retrospective designs, we only found 12 prospective 100 cohort studies investigating the risk of selected psychiatric disorders following diagnosis of 101 cardiovascular disease (summarized in Table S1, Supplementary Appendix). While these 102 prospective studies suggest a positive association between hypertension, heart disease, and stroke with depressive symptoms^{11,13–15} and stress-related disorders,¹⁶ they were limited to 103 elderly populations,^{17,18} and using self-reported ascertainment of psychiatric outcomes.^{17,18} 104 105 Only few of these studies addressed incident or first diagnosed psychiatric disorders among 106 patients with CVD, e.g. exlcuding patients with history of psychiatric disorders, and no study 107 addressed the issue of familial confounding. Indeed, genetic correlation between these two complex diseases have recently been documented ^{19–21} as well as the importance of early life 108 environment for the development of both cardiovascular disease²² and psychiatric disorders.²³ 109

110	It is therefore unknown whether the reported association between CVD and psychiatric
111	disorder can be attributed to unmeasured confounding shared within families. ^{19–21} Thus, a
112	comprehensive evaluation of the association between all CVDs and risk of any incident
113	psychiatric disorder, addressing the abovementioned shortcomings, is warranted.
114	With up to thirty years of follow-up and with nationwide complete information on family
115	links in Sweden, we aimed to comprehensively investigate the association between CVD
116	diagnosed in specialist care and subsequent risk of incident psychiatric disorders while
117	accounting for familial factors through a sibling comparison. We further aimed to estimate the
118	potential role of psychiatric comorbidity in cardiovascular mortality among patients with
119	CVD.
120	
121	Materials and Methods
122	Study Design
122 123	Study Design The Swedish Patient Register contains national information on inpatient care with complete
	• •
123	The Swedish Patient Register contains national information on inpatient care with complete
123 124	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-
123 124 125	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born
123 124 125 126	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we
123 124 125 126 127	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any
123 124 125 126 127 128	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31
123 124 125 126 127 128 129	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31 December 2016 (N=986 726). Patients diagnosed with CVD before age 5 (N=6 091, probable
 123 124 125 126 127 128 129 130 	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31 December 2016 (N=986 726). Patients diagnosed with CVD before age 5 (N=6 091, probable congenital heart disease) or with a history of any psychiatric disorder before the diagnosis of
 123 124 125 126 127 128 129 130 131 	The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001. ²⁵ The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932. ²⁶ Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31 December 2016 (N=986 726). Patients diagnosed with CVD before age 5 (N=6 091, probable congenital heart disease) or with a history of any psychiatric disorder before the diagnosis of CVD (N=111 579) were excluded, leaving 869 056 patients in the analysis (Fig S1,

134	Through the Multi-Generation Register, we identified all full siblings of patients with CVD
135	(58.6% of all CVD patients) who were alive and free of CVD and psychiatric disorder at the
136	time when their affected sibling was diagnosed (N=910 178). In addition, for each patient
137	with CVD, we randomly selected 10 age- and sex-matched individuals from the general
138	population who were free of CVD or psychiatric disorder when the index patient was
139	diagnosed (N=8 690 560). The date of CVD diagnosis for the index patient was used as the
140	index date for their unaffected siblings and matched population controls.
141	All study participants were followed from the index date until first diagnosis of any
142	psychiatric disorder, death, emigration, first diagnosis of CVD (for unaffected siblings and
143	matched population controls), or the end of the study period (31 December 2016), whichever
144	occurred first.
145	
146	Ascertainment of Cardiovascular Disease and Psychiatric Disorder
147	We defined CVD as any first inpatient or outpatient hospital visit with CVD as the primary
148	diagnosis from the Swedish Patient Register. Incident psychiatric disorder was defined as any
149	first inpatient or outpatient hospital visit with psychiatric disorder as the primary diagnosis.
150	We used the 9 th and 10 th Swedish revisions of the International Classification of Diseases
151	(ICD-9 and 10) codes to identify CVD and psychiatric disorders and their subtypes (Table S2,
152	Supplementary Appendix). In line with previous study, ²⁷ we classified CVD as ischemic heart
153	disease, cerebrovascular disease, emboli/thrombosis, hypertensive disease, heart failure, and
154	arrhythmia/conduction disorder. We classified psychiatric disorders as non-affective
155	
	psychotic disorders, affective psychotic disorders, alcohol or drug misuse, mood disorders

157 personality disorders.²⁸

158 Covariates

159	We extracted socioeconomic information for each participant, including educational level,
160	individualized family income and cohabitation status, from the Longitudinal Integration
161	Database for Health Insurance and Labor Market. ²⁹ Missing information on socioeconomic
162	status was categorized as unknown or missing group. A history of somatic diseases was
163	defined as having any of the following conditions before the index date: chronic pulmonary
164	disease, connective tissue disease, diabetes, renal diseases, liver disease, ulcer diseases,
165	malignancies, and HIV infection/AIDS (Table S2, Supplementary Appendix). We defined a
166	family history of psychiatric disorders as a diagnosis of any psychiatric disorder among
167	biological parents and full siblings of the study participants before the index date according to
168	the Swedish Patient Register.
169	Statistical Analysis
170	We used flexible parametric survival models to estimate the time-varying association between
170 171	We used flexible parametric survival models to estimate the time-varying association between CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of
171	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of
171 172	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected
171 172 173	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of
171 172 173 174	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the
 171 172 173 174 175 	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within one year of CVD diagnosis and beyond one year. Hazard ratios (HRs) and
 171 172 173 174 175 176 	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within one year of CVD diagnosis and beyond one year. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were derived from stratified Cox regression models,
 171 172 173 174 175 176 177 	CVD and subsequent risk of incident psychiatric disorders, ³⁰ by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within one year of CVD diagnosis and beyond one year. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were derived from stratified Cox regression models, using time since the index date as the underlying time scale. We estimated HRs for any

- 181 diseases (no or yes), and family history of psychiatric disorder (no or yes). In the sibling
- 182 comparison, all Cox models were stratified by sibling sets and adjusted for sex, birth year,

183 educational level, individualized family income, cohabitation status, and history of somatic 184 diseases. In the population comparison, all Cox models were stratified by the matching 185 variables birth year and sex and adjusted for all abovementioned covariates plus family 186 history of psychiatric disorder. 187 To study the impact of additional cardiovascular comorbidity (i.e., patients with another type 188 of CVD after diagnosis of the first CVD), we analyzed the association by presence or absence 189 of cardiovascular comorbidity after the index date according to the type of first CVD. This 190 analysis was restricted to follow-up beyond one year to focus on patients who survived their 191 first CVD to be able to receive the diagnosis of another CVD. As a patient with CVD might 192 have different types of CVD, we identified all diagnoses of CVD during follow-up and 193 considered CVD comorbidity as a time-varying variable through splitting the person-time 194 according to each diagnosis. 195 Because the Swedish Patient Register includes only information related to specialist care, we 196 might have misclassified patients with psychiatric symptoms who were only attended by 197 primary care. In a sensitivity analysis, we excluded also individuals with prescribed use of 198 psychotropic drugs before the index date (ascertained from the Swedish Prescribed Drug 199 Register including information on all prescribed medication use in Sweden since July 2005), 200 and followed the remaining participants during 2006-2016. Use of psychotropic drugs during 201 follow-up was also considered as having psychiatric disorder in this analysis. 202 To study rate of cardiovascular mortality (ascertained from the Swedish Causes of Death 203 Register) in relation to psychiatric comorbidities after CVD diagnosis, we plotted Kaplan-204 Meier survival curves beyond the first year of follow-up for CVD patients with or without a 205 diagnosis of psychiatric disorder during the first year of follow-up, separately. In addition to 206 this 1-year time window, we also studied six months or two years since CVD diagnosis, to

- 207 assess the robustness of these survival curves. We calculated the HRs of cardiovascular
- 208 mortality for these two groups of patients using Cox regression model.
- 209 Analyses were performed in STATA 17.0 (StataCorp LP). All tests were two sided and
- 210 P<0.05 was used as statistically level of significance. The study was approved by the Ethical
- 211 Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32).
- 212 Role of the funding source
- 213 The funders of the study had no role in study design, data collection, data analysis, data
- 214 interpretation, or writing of the report.

215

216 Results

- 217 The median age at index date was 60 years for CVD patients and 55 years for their unaffected
- 218 full siblings (Table 1). 59.2% of the CVD patients and 48.4% of their unaffected siblings
- 219 were male. CVD patients were more likely to have a history of somatic diseases than their
- unaffected siblings and matched population controls (15.6% vs. 8.8% and 11.0%). The most
- 221 common diagnoses among the CVD patients were ischemic heart diseases (24.5%),
- arrhythmia/conduction disorders ($24 \cdot 2\%$), and hypertensive diseases ($17 \cdot 3\%$). The majority
- 223 of the CVD patients had only one CVD diagnosis (without additional CVD comorbidities)
- during follow-up (69.7%).
- 225

226	Table 1. Characteristics of CVD patients diagnosed in Sweden between 1987 and 2016,
227	their unaffected siblings and matched population controls.

Characteristics	Sibling comparison		Population comparison	
	CVD patients	Unaffected full	CVD patients	Matched
	(N=509 467)	siblings (N=910	(N=869 056)	population
		178)		controls (N=8 690
				560)
Median age at index date in years (IQR)	57 (48-65)	55 (46-63)	60 (51-68)	60 (51-68)
Median follow-up time in years (IQR)	8.1 (3.7-13.7)	8.1 (3.8-13.7)	7.7 (3.3-13.2)	7.1 (3.2-12.4)
Male sex	308 203 (60.5)	440 177 (48.4)	514 388 (59.2)	5 143 880 (59.2)

Educational level				
<9 years	149 555 (29.4)	261 752 (28.8)	272 960 (31.4)	2 294 482 (26.4)
9-12 years	225 548 (44.3)	413 702 (45.5)	376 917 (43.4)	3 548 338 (40.8)
>12 years	134 364 (26.4)	234 724 (25.8)	219 179 (25.2)	2 847 740 (32.8)
Yearly individualized family income				
level				
Top 20%	1 079 90 (21.2)	175 658 (19.3)	139 098 (16.0)	1 757 726 (20.2)
Middle	301 706 (59.2)	549 842 (60.4)	535 109 (61.6)	5 152 938 (59.3)
Lowest 20%	99 485 (19.5)	184 588 (20.3)	192 858 (22.2)	1 706 931 (19.6)
Unknown	286 (0.1)	90 (0.0)	1 991 (0.2)	72 965 (0.8)
Cohabitation status				
Non-cohabitating	223 134 (43.8)	392 256 (43.1)	373 337 (43.0)	3 744 116 (43.1)
Cohabitating	286 047 (56.2)	517 832 (56.9)	493 728 (56.8)	4 873 479 (56.1)
Missing	286 (0.1)	90 (0.0)	1 991 (0.2)	72 965 (0.8)
History of somatic disease ^a	71 273 (14.0)	79 679 (8.8)	135 473 (15.6)	955 030 (11.0)
Family history of psychiatric disorder ^b	133 094 (26.1)	251 237 (27.6)	209 957 (24.2)	2 003 161 (23.1)
Type of first onset cardiovascular				
disease				
Ischemic heart disease	122 084 (24.0)	-	212 737 (24.5)	-
Cerebrovascular disease	71 030 (13.9)	-	126 860 (14.6)	-
Emboli and thrombosis	25 338 (5.0)	-	42 857 (4.9)	-
Hypertensive disease	89 818 (17.6)	-	150 337 (17.3)	-
Heart failure	15 726 (3.1)	-	30 469 (3.5)	-
Arrhythmia/conduction disorder	126 738 (24.9)	-	210 654 (24.2)	-
Others	58 733 (11.5)	-	95 142 (11.0)	-
Number of cardiovascular diagnoses				
during follow-up				
One	365 266 (71.7)	-	605 615 (69.7)	-
Two	99 921 (19.6)	-	179 472 (20.7)	-
Three or more	44 280 (8.7)	-	83 969 (9.7)	-

228 IQR: interquartile range. CVD: cardiovascular disease

229 ^a History of somatic diseases included chronic pulmonary disease, connective tissue disease, diabetes, renal

230 diseases, liver diseases, ulcer diseases and HIV infection/AIDS that diagnosed before index date.

^b The difference between exposed patients and unaffected full siblings was due to different number of siblings

232 for exposed patients. The family history of psychiatric disorder was constant within each family.

234

235 During up to thirty years of follow-up, the crude incidence rates of psychiatric disorder were

236 7.1, 4.6 and 4.0 per 1000 person-years among CVD patients, their unaffected full siblings,

and matched population controls, respectively (Table S3, Supplementary Appendix).

238 Compared with unaffected siblings, CVD patients showed an increased risk of incident

239 psychiatric disorder, especially immediately after diagnosis (Fig 1). The risk declined rapidly

240 within the first few months after diagnosis and decreased gradually thereafter: the HR was


241 2.74 (95% CI 2.62 to 2.87) within first year and 1.45 (95% CI 1.42 to 1.48) beyond first year

242 (Table S4, Supplementary Appendix). The risk increment was noted in all types of psychiatric

²³³

- 243 disorders within and beyond first year of follow-up (Fig 2). Overall, the observed risk
- 244 increase was similar in sibling and population comparisons, although the HR of non-affective
- 245 psychotic disorders beyond one year of CVD diagnosis was smaller in the sibling comparison
- than in the population comparison. During the entire follow-up, we found similar positive
- 247 associations across sex, age at index date, age at follow-up, history of somatic diseases and
- 248 family history of psychiatric disorders (Table S3). A greater risk increment was observed in
- 249 recent calendar years than earlier years.

- Figure 1. Time-varying hazard ratios for an incident psychiatric disorder among CVD patients, compared with their unaffected full
- 252 siblings (sibling comparison) or matched population controls (population comparison), by time of follow-up (<1 year and >=1 year from
- 253 CVD diagnosis)*






* CVD: cardiovascular disease. Time-varying hazard ratios and 95% confidence intervals were derived from flexible parametric survival models, allowing the effect of
 psychiatric disorder to vary over time. A spline with 5 df was used for the baseline rate, and 3 df was used for the time-varying effect. All models were adjusted for age at
 index date, sex, educational level, yearly individualized family income, cohabitation status, history of somatic diseases, as well as family history of psychiatric disorder (for

262 population comparison).

263 Figure 2. Hazard ratios with 95% confidence intervals for different types of psychiatric disorder among CVD patients compared with

their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)

265




266

* CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population
 comparison, controlling for age at index date, sex, educational level, individualized family income, cohabitation status, history of somatic diseases, and family history of

269 psychiatric disorder (in population comparison). Time since index date was used as underlying time scale.

- 270 We found an increased risk of incident psychiatric disorder among all groups of CVD patients,
- 271 with the most marked risk increase observed among patients with cerebrovascular disease and
- 272 heart failure (Fig 3). A greater risk increase of incident psychiatric disorder was noted among
- 273 CVD patients with additional cardiovascular comorbidities beyond one year of first CVD
- 274 diagnosis compared with CVD patients without such comorbidities, except among those with
- 275 heart failure (Fig S2, Supplementary Appendix). We found a similar positive association
- between CVD and risk of incident psychiatric disorder, when including use of psychotropic
- drugs as a definition of psychiatric disorder (Table S5, Supplementary Appendix).

Figure 3. Hazard ratios with 95% confidence intervals for psychiatric disorders among different groups of CVD patients compared with their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)^{*}




280 281

281 * CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population 282 comparison, controlling for age at index date, sex, education level, individualized family income, cohabitation status, history of somatic diseases, and family history of 283 psychiatric disorder (in population comparison). Time since index date was used as underlying time scale. We identified all cardiovascular diagnoses during follow-up and 284 considered CVD comorbidity as a time-varying variable by grouping the person-time according to each diagnosis.

- 286 CVD patients diagnosed with subsequent psychiatric disorder showed a reduced CVD-
- 287 specific survival compared with patients without such diagnosis (Fig 4, and Supplementary
- Appendix Fig S3 and S4). The HR of cardiovascular death was 1.55 (95% CI 1.44 to 1.67)
- 289 when comparing CVD patients with a diagnosis of psychiatric disorder to patients without
- such diagnosis (mortality rate, 9.2 and 7.1 per 1 000 person-years, respectively).
- 291

Figure 4. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during the first year of follow-up^{*}



294 295

* CVD: cardiovascular disease. Time since index date was used as underlying time scale. 90.36% of CVD patients (N=785,287) survived the first year of follow-up and included in this analysis.

297

298

299 Discussion

300 Our large population-based sibling-controlled cohort study including all patients diagnosed

- 301 with their first CVD between 1987 and 2016 in Sweden, their unaffected full siblings, as well
- 302 as a set of randomly selected unaffected population controls reveals a robust association
- 303 between CVD and subsequent risk of incident psychiatric disorder. We found that patients

304 with CVD were at elevated risk of various types of psychiatric disorders, independent of 305 confounding factors shared within families and history of somatic diseases. The risk 306 increment was greatest during the year after CVD diagnosis, indicating an opportunity for 307 clinical surveillance in a high-risk time window. Further, an occurrence of psychiatric 308 comorbidity after CVD diagnosis was associated with an approximately 55% increased risk of 309 subsequent death from cardiovascular causes. This finding further underscores the importance 310 of surveillance and, if needed, treatment of psychiatric comorbidities among newly diagnosed 311 CVD patients.

312 Strengths and Limitations

313 The strengths of our study include its large sample size of the entire Swedish nation and the 314 prospective study design with sibling comparison that significantly alleviates concerns of 315 familial confounding from shared genetic and early-life environmental factors between 316 siblings. The Swedish population and health registers provide the opportunity to obtain 317 complete follow-up as well as prospectively and independently collected information on 318 disease identification, minimizing the risk of selection and information biases. The large 319 sample size of our study further enables detailed subgroup analyses by types of CVD, types of 320 psychiatric disorders, and patient characteristics.

321 Some limitations need to be acknowledged. First, we identified patients with CVD and

322 psychiatric disorder through inpatient or outpatient hospital visit. The later inclusion of

323 outpatient records in the Swedish Patient Register may lead to underestimation of the actual

324 numbers of patients with CVD and psychiatric disorder, especially those with relatively

325 milder symptoms. Second, we missed individuals attended in primary care, which may

326 underestimate the proportion of individuals with history of psychiatric problems at study

- 327 entry. To alleviate such concerns, we additionally considered the use of prescribed
- 328 psychotropic drugs and found similar results. Further, patients with CVD have an established

329 contact with health care and may therefore be more likely than others to be diagnosed with 330 psychiatric disorder. Although such surveillance bias may to some extent explain the 331 increased risks during the first few months after CVD diagnosis, it is unlikely that the risk 332 elevation during the entire follow-up is attributed to such bias. Finally, we could not directly 333 control for lifestyle factors (e.g., smoking, diet, and physical exercise) and therefore cannot 334 exclude the possibility of residual confounding not fully controlled for in the sibling 335 comparison.

555 comparison.

336 Comparison with other studies

337 Our findings are consistent with the existing literature suggesting a positive association 338 between CVD and different types of psychiatric disorders. In previous studies, an increased risk of depression^{13–15} and anxiety¹¹ was noted after diagnosis of stroke,^{11,13–15} hypertension,¹⁷ 339 coronary artery disease³¹ and atrial fibrillation.³² Such risk elevations has been suggested to 340 be persistent over time, ^{10,33,34} and, in parallel with our findings, associated with compromised 341 survival.^{8,35,36} However, the evidence from prospective cohort studies with a long and 342 343 complete follow-up as well as with a thorough control of confounding factors and comorbid 344 conditions has, up to this point, been limited. Our study therefore complements previous 345 findings revealing a positive association between a broader range of CVDs and subsequent 346 risk of incident psychiatric disorder, using a large cohort with control of various confounding 347 factors. We found the association to be robust both in sibling and population comparisons, 348 and after additional adjustment for various comorbidities including other additional CVDs, 349 indicating that the association is unlikely explained by shared familial factors and various 350 comorbidities. We showed that CVD patients with psychiatric comorbidity was associated 351 with an increased risk of subsequent CVD death, highlighting the importance of surveillance 352 and prevention on psychiatric comorbidities for those newly diagnosed CVD patients.

353 The association between CVD and psychiatric disorders was noted both in men and women, 354 across all age groups and calendar periods, as well as among individuals with or without a 355 history of somatic diseases and family history of psychiatric disorders. Previous studies have 356 indicated that major depression was more commonly recognized among individuals with multimorbidity (more than one CVD diagnosis) than those with only one condition.³⁷ In our 357 358 study, about 30% of the CVD patients developed one or more cardiovascular comorbidities 359 during follow-up, and a higher risk of psychiatric disorder was indeed noted among patients 360 with multiple CVD diagnoses. A compromised survival from CVD cause was indeed 361 observed among most patients with common types of first CVD diagnosis and comorbid with 362 psychiatric disorder.

363 **Potential mechanisms**

364 The pathophysiological mechanisms linking CVD and psychiatric disorders are complex and

365 not well understood, and may vary with specific diagnoses of CVD and psychiatric disorders.

366 The highly increased risk noted immediately after CVD diagnosis may indicate a direct

367 impact of stress reaction of being diagnosed with a life-threatening disease.³⁸ In addition, it

368 has been proposed that biological alterations in the cardiovascular system to a severe stress

369 response may increase the risk of various psychiatric disorders.³⁹ For example,

370 cardiovascular risk factors including hypercoagulability, dyslipidemia, and an impaired

371 immune response have been associated with impaired psychological health.³⁹ Some biological

372 changes in patients with coronary heart disease (e.g., decreased heart rate variability,

373 increased arterial stiffness, and endothelial dysfunction) have been observed in patients with

depressive and anxiety disorders.^{40–42} Chronic inflammation may induce the development of

- 375 atherosclerosis and arterial thrombosis, and elevation in inflammatory biomarkers (i.e., IL-6
- and C-reactive protein) has been reported in various psychiatric disorders including post-

377	traumatic stress disorder and major depression. ^{43–45} Other behavioral and psychosocial factors
378	may as well interact with these pathways and need to be understood further.
379	Conclusions
380	Using a large population-based sibling-controlled cohort with up to thirty years of follow-up,
381	we demonstrate that patients with CVD have an increased risk of first-diagnosed psychiatric
382	disorder, independent of familial background, history of somatic diseases, and other
383	cardiovascular comorbidities. Our study further indicates an impact of psychiatric
384	comorbidities on cardiovascular mortality among patients with CVD, motivating increased
385	surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.
386	
387	
388	Competing interest: The authors declare that there is no conflict of interest.
389	
390	Author Contributions: Drs Shen, Fang, and Valdimarsdóttir had full access to all the data in
391	the study and take responsibility for the integrity of the data and the accuracy of the data.
392	Concept and design: Shen, Fang, and Valdimarsdóttir.
393	Acquisition, analysis, or interpretation of data: All authors.
394	Drafting of the manuscript: Shen, Fang, and Valdimarsdóttir.
395	Statistical analysis: Shen, Song, Fang, and Valdimarsdóttir.
396	Obtained funding: Fang, Valdimarsdóttir and Sullivan.
397	Administrative, technical, or material support: Shen, Fang, Valdimarsdóttir, Yu and Ye.
398	Supervision: Fang and Valdimarsdóttir.
399	

400	Role of the Funder: The funding sources had no role in the design and conduct of the study;
401	collection, management, analysis, and interpretation of the data; preparation, or approval of
402	the manuscript; and decision to submit the manuscript for publication.
403	
404	Ethical approval: The study was approved by the Ethical Vetting Board in Stockholm,
405	Sweden (DNRs 2012/1814-31/4 and 2015/1062-32). Informed consent to each participant was
406	waived by Swedish law in nationwide registry data.
407	
408	Data availability statement: Data analyses were performed in STATA 17.0 (StataCorp LP).

409 STATA script used in the primary analyses has been made available as supplementary

410 appendix. Aggregated data used for generating figures are available in supplementary

411 appendix. The original data used in this study are owned by the Swedish National Board of

412 Health and Welfare and Statistics Sweden. The authors are not able to make the dataset

413 publicly available according to the Public Access to Information and Secrecy Act in Sweden.

414 Any researchers (including international researchers) interested in accessing the data can send

415 request to the authorities for data application by: 1) apply for ethical approval from local

416 ethical review board; 2) contact the Swedish National Board of Health and Welfare

417 (https://bestalladata.socialstyrelsen.se/, email: registerservice@socialstyrelsen.se) and/or

418 Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email:

419 scb@scb.se) with the ethical approval and submit a formal application for access to register

420 data. The same contacts can be used for detailed information about how to apply for access to

421 register data for research purposes."

- 423 **Transparency declaration:** UV affirms that the manuscript is an honest, accurate, and
- 424 transparent account of the study being reported; that no important aspects of the study have
- 425 been omitted; and that any discrepancies from the study as planned have been explained.

426

428 **REFERENCS**

- Lu D, Andersson TML, Fall K, et al. Clinical Diagnosis of Mental Disorders Immediately
 Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. *JAMA Oncol.* 2016;2(9):1188-1196. doi:10.1001/jamaoncol.2016.0483
- 432 2. Shen Q, Lu D, Schelin MEC, et al. Injuries before and after diagnosis of cancer:
 433 nationwide register based study. *BMJ*. Published online August 31, 2016:i4218.
 434 doi:10.1136/bmj.i4218
- 3. Zhu J, Fang F, Sjölander A, Fall K, Adami HO, Valdimarsdóttir U. First-onset mental
 disorders after cancer diagnosis and cancer-specific mortality: a nationwide cohort study. *Ann Oncol.* 2017;28(8):1964-1969. doi:10.1093/annonc/mdx265
- 438
 438
 440
 439
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
- 5. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart Failure: A
 Meta-Analytic Review of Prevalence, Intervention Effects, and Associations With
 Clinical Outcomes. *J Am Coll Cardiol*. 2006;48(8):1527-1537.
- 444 doi:10.1016/j.jacc.2006.06.055
- 6. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute
 myocardial infarction. *J Gen Intern Med.* 2006;21(1):30-38. doi:10.1111/j.15251497.2005.00269.x
- 448
 448
 449
 449
 449 outcome in survivors of a myocardial infarction. *Psychosom Med.* 2004;66(4):521-526.
 450 doi:10.1097/01.psy.0000126199.05189.86
- 451 8. Doering LV, Moser DK, Riegel B, et al. Persistent comorbid symptoms of depression and
 452 anxiety predict mortality in heart disease. *Int J Cardiol*. 2010;145(2):188-192.
 453 doi:10.1016/j.ijcard.2009.05.025
- Wrenn KC, Mostofsky E, Tofler GH, Muller JE, Mittleman MA. Anxiety, anger, and
 mortality risk among survivors of myocardial infarction. *Am J Med.* 2013;126(12):1107doi:10.1016/j.amjmed.2013.07.022
- Lincoln NB, Brinkmann N, Cunningham S, et al. Anxiety and depression after stroke: a 5
 year follow-up. *Disabil Rehabil*. 2013;35(2):140-145.
 doi:10.3109/09638288.2012.691939
- 460 11. Morrison V, Pollard B, Johnston M, MacWalter R. Anxiety and depression 3 years
 461 following stroke: demographic, clinical, and psychological predictors. *J Psychosom Res.*462 2005;59(4):209-213. doi:10.1016/j.jpsychores.2005.02.019
- 463
 464
 464
 464
 465
 12. Romanelli J, Fauerbach JA, Bush DE, Ziegelstein RC. The significance of depression in older patients after myocardial infarction. *J Am Geriatr Soc.* 2002;50(5):817-822.
 465
 465
 466
 467
 468
 469
 469
 469
 469
 469
 469
 469
 460
 460
 460
 460
 460
 460
 461
 461
 461
 462
 462
 463
 464
 464
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465

466	 Wium-Andersen IK, Wium-Andersen MK, Jørgensen MB, Osler M. Anti-inflammatory
467	treatment and risk for depression after first-time stroke in a cohort of 147 487 Danish
468	patients. J Psychiatry Neurosci JPN. 2017;42(5):320-330. doi:10.1503/jpn160244
469	 Baccaro A, Wang YP, Candido M, et al. Post-stroke depression and cognitive impairment:
470	Study design and preliminary findings in a Brazilian prospective stroke cohort (EMMA
471	study). J Affect Disord. 2019;245:72-81. doi:10.1016/j.jad.2018.10.003
472	 Pohjasvaara T, Vataja R, Leppävuori A, Kaste M, Erkinjuntti T. Depression is an
473	independent predictor of poor long-term functional outcome post-stroke. <i>Eur J Neurol</i> .
474	2001;8(4):315-319. doi:10.1046/j.1468-1331.2001.00182.x
475	 Chang JC, Yen AMF, Chen HH, et al. Comorbid diseases as risk factors for incident
476	posttraumatic stress disorder (PTSD) in a large community cohort (KCIS no.PSY4). Sci
477	Rep. 2017;7:41276. doi:10.1038/srep41276
478	 Petersson S, Mathillas J, Wallin K, Olofsson B, Allard P, Gustafson Y. Risk factors for
479	depressive disorders in very old age: a population-based cohort study with a 5-year
480	follow-up. Soc Psychiatry Psychiatr Epidemiol. 2014;49(5):831-839.
481	doi:10.1007/s00127-013-0771-2
482	 Zhang X, Norton J, Carrière I, Ritchie K, Chaudieu I, Ancelin ML. Risk factors for late-
483	onset generalized anxiety disorder: results from a 12-year prospective cohort (the
484	ESPRIT study). <i>Transl Psychiatry</i> . 2015;5(3):e536. doi:10.1038/tp.2015.31
485	 Barnett JH, Smoller JW. The genetics of bipolar disorder. <i>Neuroscience</i>.
486	2009;164(1):331-343. doi:10.1016/j.neuroscience.2009.03.080
487	 Kathiresan S, Srivastava D. Genetics of Human Cardiovascular Disease. <i>Cell.</i>
488	2012;148(6):1242-1257. doi:10.1016/j.cell.2012.03.001
489	 Rødevand L, Bahrami S, Frei O, et al. Polygenic overlap and shared genetic loci between
490	loneliness, severe mental disorders, and cardiovascular disease risk factors suggest
491	shared molecular mechanisms. <i>Transl Psychiatry</i> . 2021;11(1):1-11. doi:10.1038/s41398-
492	020-01142-4
493 494 495	22. Kelishadi R, Poursafa P. A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. <i>Curr Probl Pediatr Adolesc Health Care</i> . 2014;44(3):54-72. doi:10.1016/j.cppeds.2013.12.005
496	 Rokita KI, Dauvermann MR, Donohoe G. Early life experiences and social cognition in
497	major psychiatric disorders: A systematic review. <i>Eur Psychiatry J Assoc Eur Psychiatr.</i>
498	2018;53:123-133. doi:10.1016/j.eurpsy.2018.06.006
499	24. D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based,
500	quasi-experimental designs in integrating genetic and social science research. Am J
501	Public Health. 2013;103 Suppl 1:S46-55. doi:10.2105/AJPH.2013.301252
502	25. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the
503	Swedish national inpatient register. <i>BMC Public Health</i> . 2011;11:450.
504	doi:10.1186/1471-2458-11-450

505 506 507	 Ekbom A. The Swedish Multi-generation Register. In: Dillner J, ed. <i>Methods in Biobanking</i>. Vol 675. Methods in Molecular Biology. Humana Press; 2011:215-220. doi:10.1007/978-1-59745-423-0_10
508	 Song H, Fang F, Arnberg FK, et al. Stress related disorders and risk of cardiovascular
509	disease: population based, sibling controlled cohort study. <i>BMJ</i> . 2019;365.
510	doi:10.1136/bmj.11255
511 512 513	28. Nevriana A, Pierce M, Dalman C, et al. Association between maternal and paternal mental illness and risk of injuries in children and adolescents: nationwide register based cohort study in Sweden. <i>BMJ</i> . 2020;369. doi:10.1136/bmj.m853
514	29. Longitudinell integrationsdatabas för sjukförsäkrings- och arbetsmarknadsstudier (LISA).
515	Statistiska Centralbyrån. Accessed May 22, 2018. http://www.scb.se/vara-
516	tjanster/bestalla-mikrodata/vilka-mikrodata-finns/longitudinella-register/longitudinell-
517	integrationsdatabas-for-sjukforsakringsoch-arbetsmarknadsstudier-lisa/
518	 Lambert PC, Royston P. Further Development of Flexible Parametric Models for Survival
519	Analysis. Stata J Promot Commun Stat Stata. 2009;9(2):265-290.
520	doi:10.1177/1536867X0900900206
521	31. Rutledge T, Kenkre TS, Bittner V, et al. Anxiety associations with cardiac symptoms,
522	angiographic disease severity, and healthcare utilization: the NHLBI-sponsored
523	Women's Ischemia Syndrome Evaluation. <i>Int J Cardiol.</i> 2013;168(3):2335-2340.
524	doi:10.1016/j.ijcard.2013.01.036
525	32. Baumgartner C, Fan D, Fang MC, et al. Anxiety, Depression, and Adverse Clinical
526	Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular
527	Research Network WAVE Study. J Am Heart Assoc. 2018;7(8).
528	doi:10.1161/JAHA.117.007814
529	 Zawadzka E, Domańska Ł. Assessment of select dimensions of patients' emotional
530	functioning at different time periods after stroke. <i>Appl Neuropsychol Adult</i> .
531	2014;21(2):87-93. doi:10.1080/09084282.2012.747959
532	34. Berg A, Palomäki H, Lehtihalmes M, Lönnqvist J, Kaste M. Poststroke depression: an 18-
533	month follow-up. <i>Stroke</i> . 2003;34(1):138-143. doi:10.1161/01.str.0000048149.84268.07
534	35. Cai W, Mueller C, Li YJ, Shen WD, Stewart R. Post stroke depression and risk of stroke
535	recurrence and mortality: A systematic review and meta-analysis. <i>Ageing Res Rev.</i>
536	2019;50:102-109. doi:10.1016/j.arr.2019.01.013
537	36. Boden R, Molin E, Jernberg T, Kieler H, Lindahl B, Sundstrom J. Higher mortality after
538	myocardial infarction in patients with severe mental illness: a nationwide cohort study. J
539	Intern Med. 2015;277(6):727-736. doi:10.1111/joim.12329
540	 Findley P, Shen C, Sambamoorthi U. Multimorbidity and persistent depression among
541	veterans with diabetes, heart disease, and hypertension. <i>Health Soc Work</i> .
542	2011;36(2):109-119. doi:10.1093/hsw/36.2.109
543	 Fang F, Fall K, Mittleman MA, et al. Suicide and Cardiovascular Death after a Cancer
544	Diagnosis. N Engl J Med. 2012;366(14):1310-1318. doi:10.1056/NEJMoa1110307

- 545 39. Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological Health, Well-Being,
 546 and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart
 547 Association. *Circulation*. Published online January 25, 2021.
- 548 doi:10.1161/CIR.000000000000947
- 549 40. Sherwood Andrew, Hinderliter Alan L., Watkins Lana L., Waugh Robert A., Blumenthal
 550 James A. Impaired Endothelial Function in Coronary Heart Disease Patients With
- 551 Depressive Symptomatology. *J Am Coll Cardiol*. 2005;46(4):656-659.
- 552 doi:10.1016/j.jacc.2005.05.041
- 41. Seldenrijk A, van Hout HPJ, van Marwijk HWJ, et al. Depression, Anxiety, and Arterial
 Stiffness. *Biol Psychiatry*. 2011;69(8):795-803. doi:10.1016/j.biopsych.2010.12.034
- 555 42. Stein PK, Carney RM, Freedland KE, et al. Severe depression is associated with markedly
 556 reduced heart rate variability in patients with stable coronary heart disease. *J Psychosom* 557 *Res.* 2000;48(4):493-500. doi:10.1016/S0022-3999(99)00085-9
- 43. Libby P. Inflammation and cardiovascular disease mechanisms. *Am J Clin Nutr*.
 2006;83(2):456S-460S. doi:10.1093/ajcn/83.2.456S
- 44. Sumner JA, Nishimi KM, Koenen KC, Roberts AL, Kubzansky LD. Posttraumatic Stress
 Disorder and Inflammation: Untangling Issues of Bidirectionality. *Biol Psychiatry*.
 2020;87(10):885-897. doi:10.1016/j.biopsych.2019.11.005
- 45. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary
 imperative to modern treatment target. *Nat Rev Immunol*. 2016;16(1):22-34.
 doi:10.1038/nri.2015.5
- 566

568	Figure legends
569	
570	Figure 1. Time-varying hazard ratios for an incident psychiatric disorder among CVD
571	patients, compared with their unaffected full siblings (sibling comparison) or matched
572	population controls (population comparison), by time of follow-up (<1 year and >=1
573	year from CVD diagnosis) [*]
574	year nom e v D anghosisy
575	C. Sibling comparison
576	D. Population comparison
577	
578	* CVD: cardiovascular disease. Time-varying hazard ratios and 95% confidence intervals were derived from
579	flexible parametric survival models, allowing the effect of psychiatric disorder to vary over time. A spline with 5
580	df was used for the baseline rate, and 3 df was used for the time-varying effect. All models were adjusted for age
581	at index date, sex, educational level, yearly individualized family income, cohabitation status, history of somatic
582	diseases, as well as family history of psychiatric disorder (for population comparison).
583	
584	
585	Figure 2. Hazard ratios with 95% confidence intervals for different types of psychiatric
586	disorder among CVD patients compared with their full siblings and matched population
587	controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)*
588	
589	* CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison
590	or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex,
591	educational level, individualized family income, cohabitation status, history of somatic diseases, and family
592	history of psychiatric disorder (in population comparison). Time since index date was used as underlying time
593	scale.
594	
595	
596	Figure 3. Hazard ratios with 95% confidence intervals for psychiatric disorders among
597	different groups of CVD patients compared with their full siblings and matched
598 599	population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)*
600	* CVD: cardiovascular disease. Cox regression models were stratified by family identifier for sibling comparison
601	or matching identifier (birth year and sex) for population comparison, controlling for age at index date, sex,
602	education level, individualized family income, cohabitation status, history of somatic diseases, and family
603	history of psychiatric disorder (in population comparison). Time since index date was used as underlying time
604	scale. We identified all cardiovascular diagnoses during follow-up and considered CVD comorbidity as a time-
605	varying variable by grouping the person-time according to each diagnosis.
606	
607	
608	Fig 4. Kaplan-Meier estimates of CVD death in CVD patients with and without incident
609	psychiatric disorder during the first year of follow-up ^a
610	
611	^a CVD: cardiovascular disease. Time since index date was used as underlying time scale. 90.4% of CVD
612	patients (N=785 287) survived the first year of follow-up and included in this analysis.
613	

Supplementary Appendix


Table S1. Summary of prospective cohort studies addressing the association between various indications of cardiovascular disease and risk of psychitric disorders/psychiatric symptoms.

Paper	Study design and database	Exposure	Outcome	Sample size and follow-up	Main findings		Control for
						familial factors?	other cardiovascular comorbidities?
Petersson S, 2014 ¹	population-based cohort study; basedline measured between 2000 and 2006	hypertansion and stroke in structured interviews	incident depressive disorders	567 very old people≥85 years; with 5 years of follow-up; .	hypertension OR 2.83 (1.08-7.42) and history of stroke OR 3.25 (1.12-9.44)	no	no
Zhang X, 2015 ²	Community-based study; random sampling between March 1999 and February 2001	arrhythmia and heart failgure in self-report questionnaire	Generalized anxiety disorder (GAD)	1711 individuals aged 65 years and above; median follow-up time was 9.7 years	arrhythmia and heart failure HR 1,67 (1.04-2.70)	no	no
Chang JC, 2017 ³	longidtudinal cohort study; a commuity health- screening program between 1999-2004 in Taiwan	clinical diagnosis of cardiovascular disease	clinical diagnosis of incident posttraumatic stress disorder (PTSD)	76,417 aged 30 years and above and mean follow-up of 3.13 (1-5) years	cardiovascular disease HR 1.45 (1.03–2.04)	no	no
Feng HP, 2016 ⁴	cohort study; National Health Insurance Research Database in Taiwan during January 1 and December 31, 2005	clinically diagnosed myocardial infarction	clinical diagnosis of anxiety or depressive disorder	1396 patients with myocardial infarction and matched 13,960 individuals without MI (63% men); follow-up of 2 years	HR 5.06 (4.61–5.54) for anxiety disorders and HR 7.23 (4.88–10.88) for depressive disorders	no	control for hypertension and cerebrovascular disease in model

Kivimäki M, 2012 ⁵	prospective cohort study; London- based office staff, self-reported questionnaire and medical records	Vascular risk assessed with the Framingham Cardiovascular, Coronary Heart Disease, and Stroke Risk Scores	New depressive symptoms identified by General Health Questionnaire (GHQ)>=5, and Center for Epidemiologic Studies Depression Scale score (CES-D)>=16, and use of antidepressant medication.	5318 participants (mean age 54.8 years, 31% women); baseline examination in 1991 and follow-up screenings in1997, 2003, and 2008	Diagnosed vascular disease (coronary heart disease or stroke) with an increased risk for depressive symptoms, OR 1.5 $(1.0 - 2.2)$ to 2.0 (1.4 - 3.0) depending on indicators	no	no
Zimmer man JA, 2009 ⁶	Logitudinal study among community dwelling elder Mexican Americans during 1993-1994	self-reported vascular risk factors (hypertension, storke and myocardial infarction)	Depressive symptom Measured with Center for Epidemiologic Studies Depression Scale (CES-D>=16)	964 participants (mean age 72) with two year of follow- up; 53% women	Hypertension: OR 2.3 (1.39-3.70); stroke: OR 0.83 (0.25-2.74); myocardial infarction: 1.48 (0.71-3.10)	no	по
Kim JM, 2006 ⁷	community-based prospective study from 2001-2003	self-reported vascular disease risk (stroke, heart disease, hypertension)	Depression assessed using the community version of the Geriatric Mental State (GMS)	661 community participants (mean age 73) with two year of follow-up; 55% women	Pre-existing heart disease: OR 2.2 (1.3- 3.7); incident stroke: OR 2.2 (1.0-5.0)	no	по
Mast BT, 2008 ⁸	Community residents	prevalent vascular disease	incidence depressive symptoms using Center for Epidemiologic Studies Depression (CES-D>8) scale.	1,796 elders ages 70–79 with two year of follow-up;	Coronary heart disease: OR 1.68 (1.09- 2.59); myocardial infarction: OR 2.69 (0.99-7.28); atrial fibrillation: OR 0.80 (0.19-3.42); left ventricular hypertrophy: OR 1.17 (0.65-2.12); congestive heart failure: OR 0.90 (0.27-3.06); hypertension: OR 1.07 (0.73-1.57); phripheral arterial disease: OR 1.58 (0.75-3.33)	no	Charlson index
Godin O, 2012 ⁹	multicenter cohort study with random sample during 1999-2010	Measures of systolic and diastolic blood pressure or using antihypertensive medication	major depressive symptoms according to the Mini- International Neuropsychiatric Interview or taking antidepressant medication	3,090 with ten years of follow-up; 59.9% female	Hypertension: RR 0.97 (0.76-1.22)	no	no

Garcia- Fabela L, 2009 ¹⁰	longitudinal study of community- dwelling persons	self-reported hypertension	depressive symptoms	3,276 persons aged 60 years and older with two year of follow-up;	Hypertension: OR 1.18 (1.01–1.40)	no	Adjust for stroke, ischemic cardiopathy in model
Simning A, 2018 ¹¹	nationally representative longitudinal survey of U.S. Medicare beneficiaries initiated in 2011	new onset heart attack or stroke in interview	PHQ-2 identified clinically significant depressive symptoms	5,643 aged 65 years and older with one year follow-up	Among those no close contact: heart attack OR 5.57 (1.68-18.44), stroke OR 4.44 (1.03-19.14); among those with close contacts: heart attack OR 1.19 (0.68-2.07), stroke OR 2.51 (1.76-3.59)	no	Adjust for medical conditions (include hypertension and heart disease)
Chuang CS, 2014 ¹²	Cohort study using National Health Insurance (NHI) data sets from Taiwan in period 2000-2002	hyperlipidermia (comorbidity as hypertension) from insurrance database	an insurance claim for diagnosis and treatment of depression	26,852 exposed and 107,408 unexposed individuals	Hypertension: HR 1.70 (1.57–1.83)	no	no
E 2 3 R 4 5 6 7 7 8	Epidemiol 49, 831–83 Zhang, X. et al (2015 Chang, JC. et al (2016 Rep 7, 41276. Feng, H-P et al. "Ris 4464. Kivimäki M et al (20 Zimmerman JA et al Sychiatry; 24: 409–4 Kim JM et al (2006).	9 5). "Risk factors for 7). "Comorbid dise k of anxiety and de 012). "Vascular risk (2009). "Vascular risk 16. . "Vascular risk factor . "Vascular disease	late-onset generalized anxiety disor eases as risk factors for incident post pressive disorders in patients with n status as a predictor of later-life dep risk and depression in the Hispanic l tors and incident late-life depression	rder: results from a 12- traumatic stress disord nyocardial infarction: A pressive symptoms: a c Established Population in a Korean population	cohort study with a 5-year follow-up." So year prospective cohort (The ESPRIT study er (PTSD) in a large community cohort (Ku a nationwide population-based cohort study ohort study." Biological Psychiatry;72:324 for the Epidemiologic Study of the Elderly n." Br J Psychiatry; 189: 26–30. lts: findings from the Health, Aging, and F	y)." Transl F CIS no.PSY y." Medicine -330 y (EPESE)."	Psychiatry 5, e536 4)." Sci e vol. 95,34 (2016): Int J Geriatr
9 10 11 H	Godin O et al (2012) ⁹ Garcia-Fabela L et a ¹ Simning A et al (20 Iealth and Aging Tree	. "Body mass index al (2009). "Hyperter 18). "The association nds Study Cohort."	nsion as a risk factor for developing on of a heart attack or stroke with de International journal of geriatric psy	depressive symptoms a pressive symptoms stra (chiatry vol. 33,1: 96-1	arginal structural model." Am J Epidemiol among community-dwelling elders." Rev I utified by the presence of a close social cor 03. nwide retrospective cohort study." Gen Ho	nvest Clin; 6 ntact: finding	51: 274–280. s from the National

Figure S1. Study design



CVD: cardiovascular disease.

* 67 745 families had more than one sibling affected by CVD.

	ICD-9	ICD-10
Any psychiatric disorder	291,292, 295-311	F10-F69
Non-affective psychotic disorders	295, 297, 298, excluding	F20-24, F28-29
	295H and 298B	
Affective psychotic disorders	296, 295H, 298B	F25, F30-31, F32.3, F33.3
Alcohol or drug misuse	291, 292, 303, 304	F10-16, F18-19
Mood disorders, excluding those with	300E, 311	F32-34, F38-39, excluding F32.3 and
psychotic symptoms		F33.3
Anxiety and stress related disorders	300A-D, 300F-H, 300W-X, 306, 307A, 308, 309	F40-48
-Acute stress reaction	308, 309A	F43.0
Eating disorders	307B, 307F	F50
Personality disorders	301	F60-63, F68-69
Any cardiovascular disease	390-438, 440,444,445	100-170, 1730, 174- 175
Ischemic heart disease	410-414	I20-I24, I25 (excluding I25.5)
Cerebrovascular disease	430-434, 436-438	160-169
Emboli and thrombosis	415, 444,445	126, 174, 175
Hypertensive disease	401-405	120, 174, 175 110-I16, I674
Heart failure	428	125.5, 142.0, 142.8, 142.9, 150
Arrhythmia/conduction disorder	426, 427	I25.5, 142.0, 142.8, 142.9, 150 I44-I49
Annythinia/conduction disorder	420, 427	144-149
Covariates: history of severe somatic conditions		
Chronic pulmonary disease	500-505, 506C	J60-J67, J684, J70, J703
Connective tissue disease	710A, 710B, 710E, 714A, 714B, 714C, 714W,714X, 725	M05, M06, M315, M32-M34, M351, M353, M360
Diabetes	250A, 250G	E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121, E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149
Diabetes with end organ damage	250D-250F	E102-E105, E107, E112-E115, E117, E122-E125, E127, E132-E135, E137, E142-E145, E147
Moderate or severe renal disease	582, 583A, 583B, 583C,	I120, I131, N032-N037, N052-N057,
	583E,	N18, N19, N250, Z490-Z492, Z940, Z992
Mild liver disease		N18, N19, N250, Z490-Z492, Z940,
Mild liver disease Moderate or severe liver disease	583E,	N18, N19, N250, Z490-Z492, Z940, Z992 B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762K764,
Moderate or severe liver disease Ulcer disease	583E, 583G, 583H, 585, 586, 588 571C, 571E,571F, 571G 572C, 572D, 572E, 572W, 456A, 456B, 456C	N18, N19, N250, Z490-Z492, Z940, Z992 B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762K764, K768, K769, Z944 I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767 K25-K28
Moderate or severe liver disease	583E, 583G, 583H, 585, 586, 588 571C, 571E,571F, 571G 572C, 572D, 572E, 572W,	N18, N19, N250, Z490-Z492, Z940, Z992 B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762K764, K768, K769, Z944 I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767
Moderate or severe liver disease Ulcer disease Any malignancy, including leukemia	583E, 583G, 583H, 585, 586, 588 571C, 571E,571F, 571G 572C, 572D, 572E, 572W, 456A, 456B, 456C	N18, N19, N250, Z490-Z492, Z940, Z992 B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762K764, K768, K769, Z944 I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767 K25-K28 C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C81-C85, C88,
Moderate or severe liver disease Ulcer disease Any malignancy, including leukemia and lymphoma	583E, 583G, 583H, 585, 586, 588 571C, 571E,571F, 571G 572C, 572D, 572E, 572W, 456A, 456B, 456C 140-172, 174-195, 200-208	N18, N19, N250, Z490-Z492, Z940, Z992 B18, K700-K703, K709, K713-K715, K717, K73, K74, K760, K762K764, K768, K769, Z944 I850, I859, I864, I982, K704, K711, K721, K729, K765, K766, K767 K25-K28 C00-C26, C30-C34, C37-C41, C43, C45-C58, C60-C76, C81-C85, C88, C90-C97

Table S2. International Classification of Diseases (ICD) codes for exposure, outcome and covariates identifications.

Table S3. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for incident psychiatric disorder among CVD patients compared with their full siblings or matched population controls, by patient characteristics

		S	Sibling com	parison		Population comparison				
	Unaffected	full siblings		CVD patients			Matched population controls			patients
	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)	HR (95% CI) ^a	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)	HR (95% CI) ^a
Overall	38 367	4.6	25 793	7.0	1.55 (1.53-1.58)	289 437	4.0	41 479	7.1	1.67 (1.65-1.69)
By sex										
male	17 368	4.4	14 196	6.4	1.51 (1.46-1.56)	147 978	3.4	22 546	6.4	1.80 (1.78-1.83)
female	20 999	4.8	11 597	8.0	1.56 (1.50-1.62)	141 459	4.9	18 933	8.0	1.58 (1.55-1.60)
By age at cohort entry										
<50	21 391	5.9	13 324	9.4	1.51 (1.47-1.55)	158 883	5.7	22 046	9.4	1.54 (1.52-1.57)
50-60	11 316	3.8	7 598	5.9	1.55 (1.48-1.62)	81 273	2.9	12 682	5.6	1.95 (1.91-1.99)
>60	5 660	3.2	4 871	5.1	1.69 (1.60-1.78)	49 281	3.1	6 751	5.3	1.74 (1.70-1.79)
By age during follow-up										
<60	25,165	10.2	16 995	15.0	1.51 (1.47-1.56)	169 074	10.5	24 592	16.4	1.48 (1.46-1.51)
>=60	13,202	2.3	8 798	3.5	1.46 (1.41-1.51)	120 363	2.1	16 887	3.9	1.77 (1.74-1.80)
By calendar year at cohort entry										
1987-1996	9 288	3.7	4 931	5.1	1.49 (1.43-1.55)	66 521	3.5	7 648	5.1	1.43 (1.39-1.46)
1997-2006	18 905	5.0	12 144	7.2	1.49 (1.45-1.54)	141 660	4.4	18 996	7.2	1.58 (1.55-1.60)
2007-2016	10 174	5.0	8 718	8.4	1.69 (1.63-1.74)	81 256	4.0	14 835	8.6	2.01 (1.97-2.04)
By history of somatic disease										
No	35 983	4.6	23 223	6.9	1.56 (1.52-1.59)	265 039	3.9	36 847	6.9	1.71 (1.69-1.73)
Yes	2 384	5.2	2 570	8.2	1.49 (1.26-1.75)	24 398	4.9	4 632	8.4	1.99 (1.86-2.12)
By family history of psychiatric disorder										
No	26 406	4.2	18 201	6.4	1.55 (1.51-1.58)	218 922	3.8	29 369	6.3	1.66 (1.64-1.68)
Yes	11 961	6.0	7 592	9.2	1.56 (1.51-1.61)	70 515	5.0	12 110	9.9	1.89 (1.84-1.94)

CVD: cardiovascular disease.

^aCox regression models, stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, adjusting for sex, birth year, educational level, individualized family income, cohabitation status, history of somatic disease and family history of psychiatric disorder. Time since index date was used as underlying time scale.


Table S4. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for incident psychiatric disorders among CVD patients compared with their full siblings or matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)

		Sibling con	nparison	Population comparison			
	No. of cases	IR (per 1000 person years)	HR (95% CI) ^a	No. of cases	IR (per 1000 person years)	HR (95% CI) ^a	
<1 year follow-up							
Full siblings/matched population controls	4 024	4.6	1.0	33 625	4.1	1.0	
CVD patients_controlled for sex, birth year, educational level, individualized family income and cohabitation status		12.6	2.76 (2.64-2.89)	9 545		3.06 (2.99-3.14)	
As above + history of somatic diseases	5 695		2.74 (2.62-2.87)		12.6	3.02 (2.95-3.09)	
As above + family history of psychiatric disorder			-			3.00 (2.93-3.07)	
>=1 year follow-up							
Full siblings/ matched population controls	36 021	4,8	1.0	271 900	4.3	1.0	
CVD patients_controlled for sex, birth year, educational level, individualized family income and cohabitation status	22.055	()	1.46 (1.43-1.49)	20.414	()	1.60 (1.58-1.61)	
As above + history of somatic diseases	23 955	6.9	1.45 (1.42-1.48)	38 414	6.9	1.56 (1.54-1.57)	
As above + family history of psychiatric disorder			-			1.54 (1.53-1.56)	

CVD: cardiovascular disease.

^aCox regression models, stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison. Time since index date was used as underlying time scale.

Figure S2. Crude incidence rates and hazard ratios with 95% confidence intervals (CIs) for an incident psychiatric disorder among different types of CVD patients compared with their full siblings or matched population controls, by number of CVD diagnoses during >=1 year of follow-up^a



CVD: cardiovascular disease.

^aCox regression models, stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison, and controlled for educational level, individualized family income, cohabitation status, as well as sex and birth year (in sibling comparison). Time since index date was used as underlying time scale. For patients with two or more CVD diagnoses, follow up time started from diagnosis of that cardiovascular comorbidity.

Table S5. Crude incidence rates (IRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) for psychiatric disorders among CVD patients compared with their full siblings or matched population controls, excluding CVD patients medicated with psychotropic drugs, by time of follow-up (<1 or >=1 year from CVD diagnosis)^a

		Sibling con	nparison [§]	Population comparison [§]			
	No. of cases	IR (per 1000 person years)	HR (95% CI) ^b	No. of cases	IR (per 1000 person years)	HR (95% CI) ^b	
<1 year follow up							
Full siblings/matched population controls	12 439	35.4	1.0	129 332	36.3	1.0	
CVD patients_controlled for sex, birth year, educational level, individualized family income and cohabitation status			3.73 (3.62-3.83)			3.62 (3.57-3.66)	
As above + history of somatic diseases	22 609	122.2	3.70 (3.60-3.81)	40 008	130.5	3.60 (3.56-3.65)	
As above + family history of psychiatric disorder			-			3.61 (3.56-3.65)	
>=1 year follow up							
Full siblings/ matched population controls	45 253	32.2	1.0	466 103	33.8	1.0	
CVD patients_controlled for sex, birth year, educational level, individualized family income and cohabitation status	21.500		1.41 (1.39-1.44)	55.054	15.4	1.39 (1.37-1.40)	
As above + history of somatic diseases	31 508	43.6	1.40 (1.38-1.43)	55 074	47.4	1.39 (1.38-1.41)	
As above + family history of psychiatric disorder]		-			1.40 (1.38-1.41)	

CVD: cardiovascular disease.

^a CVD patients diagnosed during 2006-2016 were included in this analysis due to the availability of data on prescribed drug. In sibling comparison, 27.8% CVD patients and 23.5% siblings were excuded due to prior medicaiton of psychotropic drugs before index date. In population comparison, 30.6% CVD patients and 25.0% population controls were excluded due to prior medicated with psychotropic drugs before index date.

^b Cox regression models, stratified by family identifier for sibling comparison or matching identifier (birth year and sex) for population comparison. Time since index date was used as underlying time scale. Definition of psychiatric disorder included hospital visits as well as use of psychotropic drugs during follow-up.

Table S6. Crude incidence rates (IRs) for psychiatric disorders among different groups of CVD patients, their full siblings and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)^a

	Sibling	comparison	Populatio	n comparison
	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)
<1 year follow-up				
Unaffected siblings/individuals	4 024	4.6	33 625	4.1
1. Ischemic heart disease	1 043	9.7	1 751	9.4
2. Cerebrovascular disease	1 039	17.0	1 793	16.7
3. Emboli and thrombosis	301	14.1	488	13.8
4. Hypertensive disease	1,124	13.5	1 941	14.0
5. Heart failure, all	177	15.6	324	15.1
6. Arrhythmia/conduction disorder	1 445	12.7	2 332	12.5
>=1 year follow-up				
Unaffected siblings/individuals	36 021	4.8	271 900	4.3
1. Ischemic heart disease	4 253	4.8	7 024	4.7
2. Cerebrovascular disease	3 354	7.5	5 539	7.5
3. Emboli and thrombosis	1 143	7.9	1 819	8.1
4. Hypertensive disease	4 294	7.5	7 000	7.6
5. Heart failure, all	614	8.4	1 080	8.2
6. Arrhythmia/conduction disorder	6 842	7.7	10 668	7.7

CVD: cardiovascular disease.

^a We identified all cardiovascular diagnoses during follow-up and considered CVD comorbidity as a timevarying variable by grouping the person-time according to each diagnosis.


Table S7. Crude incidence rates (IRs) of different types of psychiatric disorder among CVD patients, their full siblings, and matched population controls, by time of follow-up (<1 or >=1 year from CVD diagnosis)

		Sibling	, comparison	n		Population comparison			
		Unaffected full siblings		CVD patients		Matched population controls		patients	
	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)	No. of cases	IR (per 1000 person years)	
<1 year follow up									
Non-affective psychotic disorders	111	0.1	125	0.3	879	0.1	227	0.3	
Affective psychotic disorders	132	0.2	131	0.3	1 177	0.1	234	0.3	
Alcohol or drug misuse	845	1.0	1 031	2.3	8 848	1.1	1 786	2.4	
Mood disorders, excluding those with psychotic symptoms	956	1.1	1 353	3.0	8 660	1.0	2 341	3.1	
Anxiety and stress related disorders	1 649	1.9	2 620	5.8	11 954	1.4	4 263	5.6	
Eating disorders	34	0.0	75	0.2	268	0.0	96	0.1	
Personality disorders	48	0.1	47	0.1	294	0.0	84	0.1	
>=1 year follow up									
Non-affective psychotic disorders	1 048	0.1	519	0.2	6 109	0.1	919	0.2	
Affective psychotic disorders	1 155	0.2	632	0.2	8 226	0.1	1 023	0.2	
Alcohol or drug misuse	7 906	1.1	5 516	1.6	66 544	1.0	8 959	1.6	
Mood disorders, excluding those with psychotic symptoms	9 079	1.2	6 072	1.7	70 301	1.1	9 852	1.8	
Anxiety and stress related disorders	14 301	1.9	9 533	2.7	108 054	1.7	14 999	2.7	
Eating disorders	269	0.0	188	0.1	1 654	0.0	264	0.1	
Personality disorders	378	0.1	261	0.1	2 235	0.0	415	0.1	


CVD: cardiovascular disease.

Figure S3. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during 1) six months or 2) two years of follow-up

1) six months of follow-up^a



2) two years of follow-up^b




CVD: cardiovascular disease.

^a Time since index date was used as underlying time scale. 94.1% of CVD patients (N=817 748) survived the six months of follow-up and included in this analysis. The hazard ratio of cardiovascular death was 1.40 (95% confidence interval 1.27 to 1.54) when comparing CVD patients with psychiatric disorder to patients without such a psychiatric diagnosis (mortality rate, 8.1 and 7.0 per 1000 person-years, respectively).

^b Time since index date was used as underlying time scale. 83.8% of CVD patients (N=728 179) survived the two years of follow-up and included in this analysis. The hazard ratio of cardiovascular death was 1.52 (95% confidence interval 1.43 to 1.62) when comparing CVD patients with psychiatric disorder to patients without such a psychiatric diagnosis (mortality rate, 9.1 and 7.4 per 1000 person-years, respectively).

Figure S4. Kaplan-Meier estimates of CVD death in CVD patients with and without incident psychiatric disorder during the first year of follow-up, according to types of first CVD diagnosis^a



CVD: cardiovascular disease.

^a Time since index date was used as underlying time scale. 90.4% of CVD patients (N=785 287) survived the first year of follow-up and included in this analysis.